

Johannes Betge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2178722/publications.pdf>

Version: 2024-02-01

52
papers

1,333
citations

471509

17
h-index

361022

35
g-index

53
all docs

53
docs citations

53
times ranked

2516
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of liver-derived bone morphogenetic protein (BMP) as a potential new candidate for treatment of colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 343-353.	3.6	3
2	Neglected geriatric assessment and overtreatment of older patients with pancreatic cancer - Results from a prospective phase IV clinical trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 662-666.	1.0	3
3	Precision medicine for metastatic colorectal cancer in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110727.	3.2	23
4	Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial).. <i>Journal of Clinical Oncology</i> , 2022, 40, 303-303.	1.6	1
5	Personalized functional profiling using <i>ex-vivo</i> patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid. <i>Cancer Biology and Therapy</i> , 2022, 23, 96-102.	3.4	3
6	Endoscopy capsule in the scrotum. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2022, 31, 147-148.	0.9	0
7	The drug-induced phenotypic landscape of colorectal cancer organoids. <i>Nature Communications</i> , 2022, 13, .	12.8	22
8	Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. <i>The Lancet Healthy Longevity</i> , 2022, 3, e417-e427.	4.6	11
9	Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to <i>YM155</i> . <i>International Journal of Cancer</i> , 2021, 148, 1948-1963.	5.1	11
10	PPAR γ induces PD-L1 expression in MSS+ colorectal cancer cells. <i>Oncolmmunology</i> , 2021, 10, 1906500.	4.6	15
11	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. <i>Cells</i> , 2021, 10, 648.	4.1	47
12	Nivolumab and ipilimumab for second-line therapy in elderly patients with advanced esophageal squamous cell cancer: Safety interim analysis of the RAMONA trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4029-4029.	1.6	2
13	Patient-Derived Organoids of Cholangiocarcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8675.	4.1	25
14	Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5979-5992.	7.0	5
15	Cancer-Associated Mutations in Normal Colorectal Mucosa Adjacent to Sporadic Neoplasia. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00212.	2.5	3
16	Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma. <i>Oncogenesis</i> , 2020, 9, 59.	4.9	6
17	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 9778.	3.3	5
18	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019, 45, 139-154.	6.1	36

#	ARTICLE	IF	CITATIONS
19	Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing. <i>Molecular Oncology</i> , 2019, 13, 1669-1683.	4.6	8
20	MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer. <i>Nature Communications</i> , 2019, 10, 2197.	12.8	126
21	A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). <i>BMC Cancer</i> , 2019, 19, 231.	2.6	19
22	CRISPR/Cas9 for cancer research and therapy. <i>Seminars in Cancer Biology</i> , 2019, 55, 106-119.	9.6	206
23	Multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for second line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS174-TPS174.	1.6	1
24	Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 503-507.	0.9	2
25	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2052-2060.	1.6	26
26	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	12.8	55
27	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). <i>BMC Cancer</i> , 2018, 18, 747.	2.6	24
28	Correlation of BMAL1 expression in colorectal cancer with resistance to anti-VEGFA therapy with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 705-705.	1.6	0
29	A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15584-e15584.	1.6	1
30	Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients. <i>Modern Pathology</i> , 2017, 30, 897-904.	5.5	33
31	Lymph node retrieval in colorectal cancer: determining factors and prognostic significance. <i>International Journal of Colorectal Disease</i> , 2017, 32, 991-998.	2.2	39
32	Multiple behavioral factors are associated with occurrence of large, flat colorectal polyps. <i>International Journal of Colorectal Disease</i> , 2017, 32, 575-582.	2.2	3
33	Identification of a novel predictive genomic biomarker for response to combination bevacizumab in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3580-3580.	1.6	2
34	Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 42949-42961.	1.8	42
35	Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. <i>Oncotarget</i> , 2017, 8, 84714-84728.	1.8	5
36	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS10124-TPS10124.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Abstract 5766: High-content microscopy-based screening of colorectal organoids. , 2017, , .		0
38	Risk Factors for Local Recurrence of Large, Flat Colorectal Polyps after Endoscopic Mucosal Resection. <i>Digestion</i> , 2016, 93, 311-317.	2.3	26
39	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. <i>Digestion</i> , 2016, 94, 129-137.	2.3	10
40	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). <i>Annals of Oncology</i> , 2016, 27, vi241.	1.2	0
41	MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 255-265.	2.8	102
42	Frequent co-occurrence of high-grade dysplasia in large flat colonic polyps (>20Åmm) and synchronous polyps. <i>BMC Gastroenterology</i> , 2015, 15, 82.	2.0	10
43	Amplicon Sequencing of Colorectal Cancer: Variant Calling in Frozen and Formalin-Fixed Samples. <i>PLoS ONE</i> , 2015, 10, e0127146.	2.5	34
44	Abstract 967: A novel regulator of Wnt-signaling in colorectal cancer. , 2014, , .		0
45	Is there a rationale to record lymphatic invasion in node-positive colorectal cancer?. <i>Journal of Clinical Pathology</i> , 2012, 65, 847-850.	2.0	2
46	Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 3706-3712.	1.5	90
47	Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. <i>Cancer</i> , 2012, 118, 2184-2184.	4.1	3
48	Intramural and extramural vascular invasion in colorectal cancer. <i>Cancer</i> , 2012, 118, 628-638.	4.1	204
49	Perineural Invasion Is a Strong and Independent Predictor of Lymph Node Involvement in Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2011, 54, e273.	1.3	4
50	Gastric cancer and concomitant renal cancer: A systematic immunohistochemical and molecular analysis. <i>Oncology Reports</i> , 2011, 26, 567-75.	2.6	6
51	Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer. <i>Acta Gastro-Enterologica Belgica</i> , 2011, 74, 516-29.	1.0	17
52	Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors. <i>International Journal of Cancer</i> , 0, , .	5.1	2